Edition:
United Kingdom

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

1.05EUR
14 Nov 2018
Change (% chg)

€-0.19 (-15.34%)
Prev Close
€1.25
Open
€1.22
Day's High
€1.23
Day's Low
€1.05
Volume
1,665,420
Avg. Vol
754,304
52-wk High
€2.77
52-wk Low
€0.87

Latest Key Developments (Source: Significant Developments)

Pharma Mar To Offer American Depositary Shares
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Pharma Mar SA ::INTENDS TO CONDUCT REGISTERED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES REPRESENTING ITS SHARES IN US.OFFERING WILL BE MADE BY MEANS OF A SHARE CAPITAL INCREASE.  Full Article

Pharma Mar To Present Results Of Phase I/II Study With Lurbinectedin In Combination With Doxorubicin In Relapsed Small-Cell Lung Cancer
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Pharma Mar SA ::TO PRESENT RESULTS OF PHASE I/II STUDY WITH LURBINECTEDIN IN COMBINATION WITH DOXORUBICIN IN RELAPSED SMALL-CELL LUNG CANCER.BELIEVES THE OVERALL SURVIVALS OBSERVED IN TRIAL IS MORE FAVORABLE THAN THOSE SEEN IN HISTORICAL TRIALS.OBSERVED OVERALL SURVIVAL OF 10.2 MONTHS IN PATIENTS TREATED WITH LURBINECTEDIN IN COMBINATION WITH DOXORUBICIN.  Full Article

Pharma Mar Says Lurbinectedin Granted Orphan Drug Status By FDA
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Pharma Mar SA ::LURBINECTEDIN HAS BEEN GRANTED ORPHAN DRUG STATUS BY UNITED STATES FDA (FOOD AND DRUG ADMINISTRATION) FOR THE TREATMENT OF SMALL CELL LUNG CANCER.  Full Article

Pharma Mar Signs Deal With Impilo Pharma For Yondelis
Friday, 27 Jul 2018 

July 27 (Reuters) - Pharma Mar Sa ::SIGNS DEAL WITH IMPILO PHARMA FOR EXCLUSIVE PROMOTION AND DISTRIBUTION OF YONDELIS IN NORDICS AND EASTERN EUROPE.SAYS WILL RECEIVE AN UP-FRONT PAYMENT OF 2 MILLION EUROS.AGREEMENT WILL REPLACE CURRENT AGREEMENT BETWEEN PHARMA MAR AND SWEDISH ORPHAN BIOVITRUM INTERNATIONAL.  Full Article

Pharma Mar Posts H1 Net Profit Of 3.1 Mln Euros
Thursday, 26 Jul 2018 

July 26 (Reuters) - Pharma Mar SA ::H1 NET PROFIT 3.1 MILLION EUROS, H1 NET SALES 107.0 MILLION EUROS.  Full Article

Pharma Mar To Cooperate With Indonesian Oceanographic Research Center On Cancer Research
Monday, 9 Jul 2018 

July 9 (Reuters) - Pharma Mar SA ::SIGNS MEMORANDUM OF UNDERSTANDING (MOU) WITH INDONESIAN OCEANOGRAPHIC RESEARCH CENTER TO RESEARCH MARINE ANTITUMOR COMPOUNDS.  Full Article

Pharma Mar Reaches Early Termination Agreement With Chugai For Zepsyre
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Pharma Mar SA ::SAYS IT HAS ENTERED INTO MUTUAL EARLY TERMINATION AGREEMENT WITH CHUGAI.REGAINS ITS RIGHTS FOR ZEPSYRE IN JAPAN AND WILL RECEIVE 3.0 MILLION EUROS FROM CHUGAI FOR EARLY TERMINATION.SAYS PROGRESSES IN CLINICAL DEVELOPMENT OF ZEPSYRE IN JAPAN.SAYS ITS ATLANTIS GLOBAL REGISTRATION TRIAL IN SMALL-CELL LUNG CANCER CONTINUES.  Full Article

Pharma Mar Requests Change Of Primary Endpoint In Atlantis Trial
Tuesday, 12 Jun 2018 

June 12 (Reuters) - Pharma Mar SA ::REQUESTS THE MODIFICATION OF PRIMARY ENDPOINT TO OVERALL SURVIVAL (OS) FOR THE ATLANTIS TRIAL.AMENDMENT WAS SUBMITTED TO FOOD AND DRUG ADMINISTRATION (FDA) AND OTHER COMPETENT AUTHORITIES TO CHANGE PRIMARY ENDPOINT OF ATLANTIS PHASE III TRIAL FROM PROGRESSION FREE SURVIVAL (PFS) TO OVERALL SURVIVAL.EXPECTS THE "TOP LINE" DATA TO READOUT IN THE H2 OF 2019 FOR LURBINECTEDIN PHASE II SMALL-CELL LUNG CANCER STUDIES.  Full Article

Pharma Mar Signs License Agreement For Aplidin With Pint Pharma International
Monday, 11 Jun 2018 

June 11 (Reuters) - Pharma Mar SA ::SIGNS COMMERCIALIZATION AND DISTRIBUTION LICENSE AGREEMENT FOR APLIDIN WITH PINT PHARMA INTERNATIONAL.SIGNS LICENSE DEAL IN ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLOMBIA, ECUADOR, MEXICO, PARAGUAY, PERU, URUGUAY AND VENEZUELA.PINT TO PAY UNDISCLOSED MILESTONE, ROYALTY PAYMENTS TO THE CO IN EXCHANGE FOR RIGHTS TO REGISTER, COMMERCIALIZE, DISTRIBUTE APLIDIN IN EACH OF THE FORESAID TERRITORIES.TO RETAIN EXCLUSIVE PRODUCTION RIGHTS AND TO SUPPLY FINISHED PRODUCT FOR CLINICAL AND COMMERCIAL USE.  Full Article

Pharma Mar Says Phase III Trial With Zepsyre In Resistant Ovarian Cancer Not Met Its Primary Endpoint
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - PHARMA MAR SA ::CORAIL PHASE III WITH ZEPSYRE IN RESISTANT OVARIAN CANCER HAS NOT MET ITS PRIMARY ENDPOINT.  Full Article

Spanish stocks - Factors to watch on Tuesday

The following Spanish stocks may be affected by newspaper reports and other factors on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy: